Skip Navigation
Skip to contents

J Korean Soc Radiol.  2014 Aug;71(2):89-96. 10.3348/jksr.2014.71.2.89.

Response Evaluation to Neoadjuvant Chemotherapy in Advanced Breast Cancer: Comparison of MRI and Positron Emission Tomography/CT (RECIST 1.1 versus PERCIST 1.0)

Affiliations
  • 1Department of Radiology, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Suwon, Korea. didi97@catholic.ac.kr
  • 2Department of Radiology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.

Abstract

PURPOSE
The aim of this study was to compare the diagnostic performances between the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) criteria on dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) and positron emission tomography Response Evaluation Criteria in Solid Tumors version 1.0 (PERCIST 1.0) criteria on positron emission tomography/CT (PET/CT) in evaluating the treatment response of neoadjuvant chemotherapy (NAC) in breast cancer patients.
MATERIALS AND METHODS
We compared MRI and PET/CT in the assessment of tumor response after NAC with the pathological response as the standard reference in 54 breast cancer patients. The tumor response was assessed by using the RECIST 1.1 criteria on DCE-MRI and PERCIST 1.0 criteria on PET/CT. The diagnostic performance of RECIST 1.1 and PERCIST 1.0 criteria was statistically analyzed and compared by receiver operating characteristic (ROC) analysis.
RESULTS
There were 21 responders and 33 non-responders according to the pathology. The discordant rate with pathological response was 37.0% for RECIST 1.1 and 55.6% for PERCIST 1.0. Twenty six patients (48.1%) were classified as responders in both MRI and PET/CT, but the final pathology showed non-response. In the ROC curve, the area under the curves (AUC) was 0.89 for RECIST 1.1 and 0.79 for PERCIST 1.0 (p < 0.001).
CONCLUSION
The RECIST 1.1 criteria on MRI showed the better diagnostic performance than PERCIST 1.0 criteria on PET/CT for the response assessment of breast cancer after NAC, although there was no statistically significant difference between both (p = 0.15).


MeSH Terms

Breast Neoplasms*
Drug Therapy*
Electrons*
Humans
Magnetic Resonance Imaging*
Pathology
Positron-Emission Tomography
Positron-Emission Tomography and Computed Tomography
ROC Curve
Full Text Links
  • JKSR
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2026 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr